Talaris Therapeutics, Inc. (NASDAQ:TALS) CEO Purchases $23,438.72 in Stock

Talaris Therapeutics, Inc. (NASDAQ:TALSGet Rating) CEO Scott Requadt acquired 5,528 shares of the business’s stock in a transaction on Tuesday, July 26th. The shares were purchased at an average price of $4.24 per share, with a total value of $23,438.72. Following the completion of the purchase, the chief executive officer now owns 466,208 shares in the company, valued at approximately $1,976,721.92. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Scott Requadt also recently made the following trade(s):

  • On Thursday, July 28th, Scott Requadt acquired 3,090 shares of Talaris Therapeutics stock. The shares were purchased at an average price of $4.25 per share, with a total value of $13,132.50.
  • On Friday, July 22nd, Scott Requadt acquired 9,444 shares of Talaris Therapeutics stock. The shares were purchased at an average price of $3.75 per share, with a total value of $35,415.00.

Talaris Therapeutics Price Performance

NASDAQ:TALS opened at $4.45 on Friday. The firm has a market capitalization of $184.51 million, a PE ratio of -2.99 and a beta of 3.77. The business’s fifty day moving average price is $5.95 and its 200 day moving average price is $7.61. Talaris Therapeutics, Inc. has a 12 month low of $2.04 and a 12 month high of $17.48.

Talaris Therapeutics (NASDAQ:TALSGet Rating) last posted its earnings results on Thursday, May 12th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.10). As a group, equities analysts anticipate that Talaris Therapeutics, Inc. will post -1.8 EPS for the current year.

Hedge Funds Weigh In On Talaris Therapeutics

Several hedge funds have recently made changes to their positions in TALS. Altium Wealth Management LLC purchased a new position in shares of Talaris Therapeutics during the fourth quarter worth about $910,000. New York State Common Retirement Fund grew its holdings in shares of Talaris Therapeutics by 32.5% during the fourth quarter. New York State Common Retirement Fund now owns 10,189 shares of the company’s stock worth $156,000 after purchasing an additional 2,500 shares during the last quarter. Northern Trust Corp grew its holdings in shares of Talaris Therapeutics by 102.5% during the fourth quarter. Northern Trust Corp now owns 168,045 shares of the company’s stock worth $2,569,000 after purchasing an additional 85,058 shares during the last quarter. ProShare Advisors LLC purchased a new position in shares of Talaris Therapeutics during the fourth quarter worth about $160,000. Finally, Ensign Peak Advisors Inc purchased a new position in shares of Talaris Therapeutics during the fourth quarter worth about $727,000. Hedge funds and other institutional investors own 74.84% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. Guggenheim dropped their price target on Talaris Therapeutics to $23.00 and set a “na” rating for the company in a research report on Monday, May 16th. Morgan Stanley cut Talaris Therapeutics from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $20.00 to $8.00 in a research note on Tuesday, July 5th. Finally, SVB Leerink lowered Talaris Therapeutics from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $21.00 to $7.00 in a research report on Thursday, June 30th.

Talaris Therapeutics Company Profile

(Get Rating)

Talaris Therapeutics, Inc operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders.

Read More

Receive News & Ratings for Talaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.